Cargando…

Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK

OBJECTIVE: To assess outcomes in patients with iron-deficient inflammatory bowel disease (IBD) treated with ferric maltol in UK real-world practice. DESIGN/METHOD: This observational, multicentre, retrospective cohort study included adults with IBD and iron-deficiency anaemia (IDA; haemoglobin ≥95 t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cummings, JR Fraser, Fraser, Aileen, Stansfield, Catherine, Beales, Ian, Sebastian, Shaji, Hoque, Sami
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907848/ https://www.ncbi.nlm.nih.gov/pubmed/33622683 http://dx.doi.org/10.1136/bmjgast-2020-000530

Ejemplares similares

Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial
por: Zoller, Heinz, et al.
Publicado: (2023)

Oral iron supplementation with ferric maltol in patients with pulmonary hypertension
por: Olsson, Karen M., et al.
Publicado: (2020)

Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion
por: Schmidt, Carsten, et al.
Publicado: (2021)

Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long‐term extension data from a Phase 3 study
por: Schmidt, C., et al.
Publicado: (2016)

Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience
por: Hoque, Sami, et al.
Publicado: (2020)

Safety, Tolerability, and Pharmacokinetics of Oral Ferric Maltol in Children With Iron Deficiency: Phase 1 Study
por: Allen, Stephen, et al.
Publicado: (2021)

Oral Ferric Maltol Does Not Adversely Affect the Intestinal Microbiome of Patients or Mice, but Ferrous Sulphate Does
por: Mahalhal, Awad, et al.
Publicado: (2021)

Impact of the coronavirus infectious disease (COVID-19) pandemic on the provision of inflammatory bowel disease (IBD) antenatal care and outcomes of pregnancies in women with IBD
por: Selinger, Christian Philipp, et al.
Publicado: (2021)

Life in lockdown: experiences of patients with IBD during COVID-19
por: Harris, Richard James, et al.
Publicado: (2020)

Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial
por: Howaldt, Stefanie, et al.
Publicado: (2021)

High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease: metabolic and clinical predictors identified by machine learning
por: McDonnell, Martin, et al.
Publicado: (2020)

Prevalence and screening for anaemia in mild to moderate Crohn's disease and ulcerative colitis in the United States, 2010–2014
por: Akhuemonkhan, Eboselume, et al.
Publicado: (2017)

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)
por: Probert, Christopher SJ, et al.
Publicado: (2018)

Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis
por: Kennedy, N. A., et al.
Publicado: (2016)

Corrigendum to: Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial
por: Howaldt, Stefanie, et al.
Publicado: (2021)

Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study
por: Sebastian, Shaji, et al.
Publicado: (2022)

Ulcerative colitis increases risk of hypertension in a UK biobank cohort study
por: He, Jinshen, et al.
Publicado: (2022)

Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource
por: Stournaras, Evangelos, et al.
Publicado: (2021)

Ferric Maltol Is Effective in Correcting Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: Results from a Phase-3 Clinical Trial Program
por: Gasche, Christoph, et al.
Publicado: (2014)

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational study
por: Goessens, Laurent, et al.
Publicado: (2021)

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)
por: Danese, Silvio, et al.
Publicado: (2019)

Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2022)

Developing a core outcome set for fistulising perianal Crohn’s disease
por: Sahnan, Kapil, et al.
Publicado: (2019)

Changing paradigms in management of inflammatory bowel disease
por: Mao, Ren, et al.
Publicado: (2022)

Environmental risk factors for inflammatory bowel disease
por: Singh, Noreen, et al.
Publicado: (2022)

New endoscopic tools in inflammatory bowel disease
por: Nardone, Olga Maria, et al.
Publicado: (2022)

Can adjuncts to bowel preparation for colonoscopy improve patient experience and result in superior bowel cleanliness? A systematic review and meta-analysis
por: Kamran, Umair, et al.
Publicado: (2020)

Ultrasonography in inflammatory bowel disease – So far we are?
por: Christian, Maaser, et al.
Publicado: (2022)

Landscape of new drugs and targets in inflammatory bowel disease
por: Vieujean, Sophie, et al.
Publicado: (2022)

Is hypertension an extra‐intestinal manifestation of inflammatory bowel disease?
por: Burisch, Johan
Publicado: (2023)

Avoiding food avoidance in patients with inflammatory bowel disease
por: Godny, Lihi, et al.
Publicado: (2023)

Faecal metabolome and its determinants in inflammatory bowel disease
por: Vich Vila, Arnau, et al.
Publicado: (2023)

Physical Fitness in Adolescence and Subsequent Inflammatory Bowel Disease Risk
por: Melinder, Carren, et al.
Publicado: (2015)

Endoscopy and histology in inflammatory bowel diseases patients: Complementary or alternatives?
por: D'Amico, Ferdinando, et al.
Publicado: (2022)

Identifying and understanding disease burden in patients with inflammatory bowel disease
por: Christensen, Katrine Risager, et al.
Publicado: (2022)

Inflammatory bowel disease cross‐sectional imaging: What's new?
por: Wang, Yang‐di, et al.
Publicado: (2022)

The role of gut microbiome in inflammatory bowel disease diagnosis and prognosis
por: Zheng, Jiaying, et al.
Publicado: (2022)

Smoking and colorectal cancer in inflammatory bowel disease: Quantity matters?
por: Marafini, Irene, et al.
Publicado: (2023)

The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association
por: Kaplan, Gilaad G, et al.
Publicado: (2010)

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
por: Cayatte, Corinne, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_iegrfodueth2rr4oqbu1or4ktr